ARTICLE | Company News

Clinigen Group, Norgine, SpePharm deal

April 7, 2014 7:00 AM UTC

Clinigen will acquire from SpePharm AG - a 50/50 JV between Norgine and SpePharm Holding - rights to Savene dexrazoxane in all markets, excluding North and South America, Israel and South Africa. The topoisomerase II (TOP2) inhibitor is marketed in the U.S. as Totect and in the EU as Savene to treat anthracycline extravasation, or the unintentional leakage of anthracycline chemotherapeutics into the perivascular or subcutaneous spaces. In 2012, Norgine and SpePharm Holding created the JV to commercialize SpePharm Holding's entire product profile, including Savene, through Norgine's commercial infrastructure. Norgine said the deal with Clinigen will provide the JV proceeds to acquire further specialty pharmaceutical products. Norgine and SpePharm AG said financial terms were not disclosed. ...